Alitretinoin for Severe Chronic Hand Eczema: What the BACH Trial Measured
Severe chronic hand eczema that remains active despite potent topical treatment can require a specialist discussion of systemic options. Alitretinoin is an oral retinoid studied in that setting. Its research is relevant to a particular difficult-to-treat hand condition, not every dry hand or every person with atopic dermatitis.
What BACH compared
The 2008 BACH trial randomized 1,032 patients with severe chronic hand eczema refractory to topical corticosteroids across 111 clinics in Europe and Canada. Two oral alitretinoin regimens were compared with placebo for up to 24 weeks. Clear-or-almost-clear hands were achieved in up to 48% of treated patients, versus 17% with placebo.
The highest reported response corresponds to a particular studied regimen; it is not the result for every dose or patient. Clear-or-almost-clear is a defined assessment at a study time point, not a permanent cure. The investigators reported median relapse times of approximately 5.5–6.2 months among responders after treatment ended, using a defined recurrence threshold.
Keep the diagnosis and comparison intact
Chronic hand eczema can involve different patterns and contributing exposures. Failure of one topical course does not by itself establish that an oral retinoid is needed. Before escalation, a specialist can review the diagnosis, actual treatment use, contact exposures and which parts of daily function remain impaired.
| Trial feature | Question for an individual review |
|---|---|
| Severe refractory disease | Does my hand condition fit this treatment discussion? |
| Up to 24 weeks of treatment | When would response and tolerability be reassessed? |
| Clear/almost-clear endpoint | How will symptoms and practical function also be followed? |
| Relapse follow-up in responders | What is the plan if symptoms return? |
Pregnancy and laboratory precautions matter
The UK Toctino prescribing information describes use in adults with severe chronic hand eczema unresponsive to potent topical corticosteroids. It states that pregnancy is an absolute contraindication and specifies a Pregnancy Prevention Programme. It also discusses lipid and thyroid changes, relevant contraindications and interactions, including avoiding concurrent tetracyclines.
This is a UK document, not proof of U.S. approval or local availability. A trial publication does not establish a prescribing indication in every country. Ask the treating specialist which locally available options are appropriate and how the actual product's labeling applies. Do not substitute another retinoid or try to import a study regimen yourself.
A percentage cannot rank unlike treatments
Our DELTA trial discussion concerns a topical medicine studied under different conditions. Comparing its percentage directly with BACH does not create a head-to-head comparison. Eligibility, background care, duration and outcome definitions can all affect the numbers.
The HECSI guide explains another hand-eczema measure. At a review, describe pain, fissures, sleep or necessary hand tasks as well as visible skin. Agree which changes would make treatment worthwhile and which adverse effects need prompt contact.
Bring all current medicines, supplements and relevant medical history. The decision needs to include monitoring and reproductive safety, not only the chance of a clearer-hand score. Everyday moisturizer has a supportive role and cannot replace an indicated systemic or topical treatment.
Make the review useful before escalation
Describing how topical treatment was actually used between visits can reveal access or application barriers without dismissing severe disease. If contact allergy remains a possibility, our discussion of patch-test interpretation during dupilumab treatment shows why test conditions and relevance matter. That study concerns a different treatment context; it is not evidence that every person with hand eczema needs dupilumab or testing while taking it.
Sources and reading notes
Prepared by the Dr. Arsy Editorial Team. Sources checked November 8, 2026. Educational information; this article does not imply independent clinician review. PubMed indexing is not NIH endorsement. The cited researchers do not endorse #003. The product image is an AI-created editorial scene based on the actual jar, not a patient photograph or a study result.